GMAB is the ticker symbol for GENMAB A/S, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks GMAB with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is GMAB a good stock to buy?

13F Pro's AI ranking engine scores GMAB at 52.8/100, ranked #1,445 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for GMAB is available at https://13fpro.ai/company/GMAB. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source GMAB data?

All GENMAB A/S fundamentals and ownership data come directly from SEC EDGAR. GENMAB A/S files with the SEC under CIK 1434265. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

GENMAB A/S GMAB

NasdaqLarge CapHealthcare

13F Pro quality score

Rank #1,445 of 2,925TOP 50%

Why it scores 53 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$3.72B

Quarter to Dec 31

Net income

$963.00M

Quarter to Dec 31

Free cash flow

$1.15B

Quarter to Dec 31

Operating margin

28.6%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026

$2.81B total

Paradigm Biocapital Advisors LP

$360.77M+64.8%

Orbis Allan Gray Ltd

$312.28M-12.0%

ALLIANCEBERNSTEIN L.P.

$231.94M-9.5%

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

$188.58M+178.8%

Deep Track Capital, LP

$155.21M+54.2%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$136.67M0.0%

BlackRock, Inc.

$128.32M+3.0%

Sofinnova Ventures Inc

$111.12M+437.7%

RENAISSANCE TECHNOLOGIES LLC

$96.64M-20.3%

TWO SIGMA INVESTMENTS, LP

$96.33M+49.9%

HARDING LOEVNER LP

$86.90M-4.5%

FIRST TRUST ADVISORS LP

$75.72M+12.0%

CITADEL ADVISORS LLC

$68.02MNew

Qube Research & Technologies Ltd

$46.40M+149.4%

MORGAN STANLEY

$44.78M-25.4%

FEDERATED HERMES, INC.

$39.81M+15.8%

GOLDMAN SACHS GROUP INC

$35.14M+37.4%

FRANKLIN RESOURCES INC

$33.04M+0.8%

Pictet Asset Management Holding SA

$29.28M-1.1%

UBS Group AG

$26.40M+222.4%

Perpetual Ltd

$25.25M+21.2%

NORTHERN TRUST CORP

$25.18M-3.6%

MILLENNIUM MANAGEMENT LLC

$25.01M+14.9%

Russell Investments Group, Ltd.

$24.27M+10.8%

ENVESTNET ASSET MANAGEMENT INC

$22.79M-3.8%

See all 295 institutional holders →

What's Driving GMAB's Business? Latest 20-F Breakdown

4/4 datapoints verified

AI-extracted from the 20-F filed 2026-02-17 — FY2025 (year ended December 31, 2025). Every figure is machine-verified against the filing text on SEC EDGAR.

Genmab reported 66% of 2025 revenue from DARZALEX royalties as patent expiration looms in 2029, while advancing commercial launches of proprietary products EPKINLY and Tivdak.

Biggest Revenue Drivers

Royalties from partnered productsApproximately 66% of total revenue

Primarily DARZALEX royalties from J&J, which accounted for 66% of 2025 revenue; patent rights expire in 2029 in US, 2031 in Europe, beginning in 2030 in Japan

Product sales from proprietary and co-developed productsIncluded in remaining revenue

Includes net sales of EPKINLY (epcoritamab) co-developed with AbbVie and Tivdak (tisotumab vedotin) co-developed with Pfizer

Biggest Revenue Drivers

Total revenue: Not disclosed in this excerpt

Royalties from partnered productsApproximately 66% of total revenue

Primarily DARZALEX royalties from J&J, which accounted for 66% of 2025 revenue; patent rights expire in 2029 in US, 2031 in Europe, beginning in 2030 in Japan

Product sales from proprietary and co-developed productsIncluded in remaining revenue

Includes net sales of EPKINLY (epcoritamab) co-developed with AbbVie and Tivdak (tisotumab vedotin) co-developed with Pfizer

Watch Items from the Filing

DARZALEX royalties represent 66% of revenue; US patent protection expires 2029, triggering anticipated material decline in royalties upon expiration and biosimilar competition.
Substantial indebtedness incurred for Merus acquisition; restrictive debt covenants limit operational flexibility and require dedication of cash flow to debt service.
CMO for Rina-S manufacturing located in China; BIOSECURE Act enacted December 2025 could restrict use of Chinese biotechnology companies, risking supply disruption and commercialization delay.
Petosemtamab Phase III trials (LiGeR-HN1, LiGeR-HN2) expected to readout in 2026; BTD designations indicate strong development pathway but no assurance of regulatory approval.
Four lawsuits filed by Chugai in Japan (2024–2025) challenging EPKINLY patent validity; Genmab and AbbVie defend vigorously but outcome uncertain.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 20-F on SEC EDGAR →

Key Metrics

Revenue

FY 2025

EDGAR

Net Income

FY 2025

EDGAR

EPS (Diluted)

FY 2025

EDGAR

Operating Margin

FY 2025

EDGAR

ROIC

FY 2025

EDGAR

Free Cash Flow

FY 2025

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/GMAB

Earnings Per Share

13fpro.ai/company/GMAB

Loading ratio trend…

GENMAB A/S reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	20-F	$3.7B	$963.0M	28.6%
FY 2024	20-F	$3.1B	$1.1B	31.1%
FY 2023	20-F	$2.4B	$631.0M	32.3%

About GENMAB A/S (GMAB): stock profile, AI score and financials

GENMAB A/S (GMAB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GMAB at 52.8/100 on a composite quality score built from its SEC filings, placing it at rank #1,445 of 2,925 stocks — the top half of the AI-ranked universe. GMAB scores in the top quartile across institutional flow (98.1), revenue growth (94.0). Areas of concern include profitability (30.0) and balance sheet strength (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (FY 2025), GENMAB A/S reports quarterly revenue of $3.7B, net income of $963.0M, an operating margin of 28.6%. Top institutional holders of GMAB by reported 13-F value include Paradigm Biocapital Advisors, Orbis Allan Gray Ltd, ALLIANCEBERNSTEIN L.P., based on the most recent SEC filings. GMAB trades on the Nasdaq exchange and files with the SEC under CIK 1434265. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GMAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GENMAB A/S directly from SEC EDGAR.

Financials through the period ended Jun 30, 2025SEC EDGAR: CIK 1434265 →

GENMAB A/S GMAB

Top Institutional Holders

What's Driving GMAB's Business? Latest 20-F Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

GMAB key financials by period

GMAB insiders

Congress trading in GMAB

About GENMAB A/S (GMAB): stock profile, AI score and financials

GENMAB A/S GMAB

Top Institutional Holders

What's Driving GMAB's Business? Latest 20-F Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

GMAB key financials by period

Companies similar to GMAB

GMAB insiders

Congress trading in GMAB

About GENMAB A/S (GMAB): stock profile, AI score and financials